- Global Expansion Plans for Metreleptin Opportunity to be Announced this Summer
- Defined Clinical Development Plan for Zuretinol Following Positive FDA Meeting
- Company Reiterates FY 2017 Total Net Revenues Guidance
Between $155 and $165 million
- Conference call to be held today at 8:30 a.m. ET
Recent Press Releases
Open-label study in patients with partial lipodystrophy-associated NASH featured in oral presentation
Vancouver, British Columbia, March 31, 2017 – Novelion Therapeutics Inc. (NASDAQ: NVLN) (TSX: NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, today announced the appointment of Mark Corrigan, M.D. to its board of directors, effective immediately. Dr. Corrigan will serve as a member of the compliance committee.